WITHUS PHARMACEUTICAL Co.,LTD. (KOSDAQ:330350)
South Korea · Delayed Price · Currency is KRW 8,860.00
+1,060.00 (13.59%)
At close: Jun 19, 2026
KOSDAQ:330350 Income Statement
Financials in millions KRW. Fiscal year is January - December.
Millions KRW. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Operating Revenue | 108,892 | 106,444 | 102,722 | 80,119 | 64,680 | 57,419 |
Other Revenue | - | - | - | -0 | - | - |
| 108,892 | 106,444 | 102,722 | 80,119 | 64,680 | 57,419 | |
Revenue Growth (YoY) | 6.23% | 3.62% | 28.21% | 23.87% | 12.65% | 7.51% |
Cost of Revenue | 39,281 | 37,614 | 37,168 | 31,481 | 26,345 | 23,894 |
Gross Profit | 69,610 | 68,830 | 65,554 | 48,638 | 38,335 | 33,525 |
Selling, General & Admin | 61,126 | 58,719 | 56,002 | 37,237 | 29,767 | 26,100 |
Research & Development | 2,616 | 2,588 | 2,297 | 1,868 | 2,357 | 1,420 |
Amortization of Goodwill & Intangibles | 1,417 | 1,337 | 1,194 | 956.43 | 576.93 | 184.34 |
Other Operating Expenses | 200.9 | 192.95 | 178.61 | 186.67 | 278.07 | 296.44 |
Operating Expenses | 65,783 | 63,168 | 59,893 | 40,729 | 33,457 | 28,639 |
Operating Income | 3,828 | 5,663 | 5,661 | 7,909 | 4,878 | 4,886 |
Interest Expense | -655.62 | -714.66 | -814.08 | -596.06 | -390.74 | -323.96 |
Interest & Investment Income | 612.47 | 611.18 | 486.88 | 727.19 | 468.62 | 392.66 |
Currency Exchange Gain (Loss) | -2.58 | 0.91 | -3.18 | 1.72 | 0.63 | -3.98 |
Other Non Operating Income (Expenses) | 992.24 | 1,122 | 147.77 | -425.51 | -435.03 | -305.14 |
EBT Excluding Unusual Items | 4,774 | 6,682 | 5,478 | 7,617 | 4,521 | 4,646 |
Gain (Loss) on Sale of Investments | 309.07 | -348.82 | -133.97 | 1,515 | -373.86 | 979.32 |
Gain (Loss) on Sale of Assets | - | - | - | 9.04 | 10.78 | -385 |
Asset Writedown | -1,819 | -1,819 | -205 | - | - | - |
Pretax Income | 3,264 | 4,514 | 5,139 | 9,141 | 4,158 | 5,240 |
Income Tax Expense | -4,028 | -452.76 | 354.3 | 1,182 | 1,679 | 976.07 |
Net Income | 7,292 | 4,967 | 4,785 | 7,959 | 2,479 | 4,264 |
Net Income to Common | 7,292 | 4,967 | 4,785 | 7,959 | 2,479 | 4,264 |
Net Income Growth | 65.27% | 3.81% | -39.88% | 221.04% | -41.86% | -35.91% |
Shares Outstanding (Basic) | 13 | 13 | 13 | 13 | 13 | 13 |
Shares Outstanding (Diluted) | 13 | 13 | 13 | 13 | 13 | 13 |
Shares Change (YoY) | -0.04% | -0.14% | 0.14% | 0.09% | -0.10% | 59.55% |
EPS (Basic) | 552.17 | 376.31 | 362.00 | 603.00 | 188.00 | 323.00 |
EPS (Diluted) | 552.17 | 376.31 | 362.00 | 603.00 | 188.00 | 323.00 |
EPS Growth | 65.34% | 3.95% | -39.97% | 220.75% | -41.80% | -59.83% |
Free Cash Flow | 3,249 | 5,483 | 7,268 | -12,044 | -9,952 | 1,354 |
Free Cash Flow Per Share | 246.01 | 415.40 | 549.86 | -912.45 | -754.70 | 102.59 |
Gross Margin | 63.93% | 64.66% | 63.82% | 60.71% | 59.27% | 58.39% |
Operating Margin | 3.52% | 5.32% | 5.51% | 9.87% | 7.54% | 8.51% |
Profit Margin | 6.70% | 4.67% | 4.66% | 9.93% | 3.83% | 7.43% |
Free Cash Flow Margin | 2.98% | 5.15% | 7.07% | -15.03% | -15.39% | 2.36% |
EBITDA | 8,000 | 9,746 | 9,438 | 10,754 | 6,826 | 6,387 |
EBITDA Margin | 7.35% | 9.16% | 9.19% | 13.42% | 10.55% | 11.12% |
D&A For EBITDA | 4,172 | 4,084 | 3,778 | 2,844 | 1,948 | 1,501 |
EBIT | 3,828 | 5,663 | 5,661 | 7,909 | 4,878 | 4,886 |
EBIT Margin | 3.52% | 5.32% | 5.51% | 9.87% | 7.54% | 8.51% |
Effective Tax Rate | - | - | 6.89% | 12.93% | 40.38% | 18.63% |
Advertising Expenses | - | 830.46 | 832.52 | 841.87 | 831.45 | 887 |